Hypofractionated radiotherapy in prostate cancer

References

• Jeman A, Bray F, Center MM et al. Global statistics. CA Cancer J. Clin.61, 69–90 (2011).
   Google Scholar
• Fradet Y, Klotz L, Trachtenberg J, Zlotta A. The burden of prostate cancer in Canada. Can. Urol. Assoc. J.3(3 Suppl. 2), S92–S100 (2009).
   Google Scholar
• Deslongchamps NB, Singh A, Haas GP. The role of prevalence in the diagnosis of prostate cancer. Cancer Control13, 158–168 (2006).
   Google Scholar
• Sakr W, Grignon DJ, Haas GP, Heilbrun LK, Pontes JE, Crissman JD. Age and racial distribution of prostatic intraepithilial neoplasia. Eur. Urol.30, 138–144 (1996).
   PubMed Web of Science ®Google Scholar
• Grover SA, Coupal L, Zowal H et al. The economic burden of prostate cancer in Canda: forecasts from the Montreal Prostate Cancer Model. CMAJ162, 987–992 (2000).
   PubMed Web of Science ®Google Scholar
• Poon I, Pintilie M, Potvin M et al. The changing costs of radiation treatment for early prostate cancer in Ontario: a comparison between conventional and conformal external beam radiotherapy. Can. J. Urol.11, 2125–2132 (2004).
   PubMedGoogle Scholar
• Konski A, Watkins-Bruner D, Feigenberg S et al. Using decision analysis to determine the cost effectiveness of intensity modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.66, 408–415 (2006).
   PubMed Web of Science ®Google Scholar
• Hall EJ, Giaccia AJ. Radiobiology for the Radiologist (6th Edition). Lippincott Williams & Wilkins, PA, USA (2006).
   Google Scholar
• Haustermans KM, Hofland I, Van Poppel H et al. Cell kinetic measurements in prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.37, 1067–1070 (1997).
   PubMed Web of Science ®Google Scholar
• Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys.43, 1095–1101 (1999).
   PubMed Web of Science ®Google Scholar
• Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low? Int. J. Radiat. Oncol. Biol. Phys.50, 1021–1031 (2001).
   PubMed Web of Science ®Google Scholar
• Dasu A. Is the alpha/beta value for prostate tumors low enough to be safely used in clinical trials? Clin. Oncol.19, 289–301 (2007).
   PubMed Web of Science ®Google Scholar
• Williams SG, Taylor JMG, Liu NG et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.64, 24–33 (2007).
   Google Scholar
• Proust-Lima C, Taylor JMG, Sécher S et al. Confirmation of a low alpha/beta ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int. J. Radiat. Oncol. Biol. Phys.79, 195–201 (2010).
   PubMed Web of Science ®Google Scholar
• Miralbell R, Roberts SA, Zubizarreta E et al. Dose–fractionation radiosensitivity of prostate cancer deduced from radiotherapy outcome of 5969 patients in seven international institutional datasets. Int. J. Radiat. Oncol. Biol. Phys.75, S81 (2009).
   Google Scholar
• Menkarios C, Vigneault É, Brochet N et al. Toxicity report of once weekly radiation therapy for low-risk prostate adenocarcinoma: preliminary results of a Phase I/II trial. Radiat. Oncol.6, 112 (2011).
   PubMed Web of Science ®Google Scholar
• King CR, Mayo CS. Is the prostate alpha/beta ratio of 1.5 from Brenner & Hall a modeling artifact? Int. J. Radiat. Oncol. Biol. Phys.47, 536–538 (2000).
   PubMedGoogle Scholar
• Wang JZ, Mayr NA, Li XA, Stewart RD. Modeling prostate cancer: in regards to Nahum et al. (Int. J. Radiat. Oncol. Biol. Phys. 57, 391–401 (2003)). Int. J. Radiat. Oncol. Biol. Phys.61, 309–310 (2005).
   PubMedGoogle Scholar
• Nahum AE, Movsas B, Horwitz EM, Stobbe CC, Chapman JD. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio. Int. J. Radiat. Oncol. Biol. Phys.57(2), 391–401 (2003).
   PubMed Web of Science ®Google Scholar
• Valdagni R, Italia C, Montanaro P et al. Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy. Radiother. Oncol.75, 74–82 (2005).
   PubMed Web of Science ®Google Scholar
• Teh BS, Ishiyama H. Hypofractionated radiotherapy for prostate cancer. Lancet Oncol.13(1), 5–6 (2012).
   Google Scholar
• Collins CD, Lloyd-Davies RW, Swan AV. Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique. Clin. Oncol. (R. Coll. Radiol.)3(3), 127–132 (1991).
   Google Scholar
• Rene N, Faria S, Cury F et al. Hypofractionated radiotherapy for favorable risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.77(3), 805–810 (2010).
   Google Scholar
• Lock M, Best L, Wong E et al. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.80(5), 1306–1315 (2011).
   Google Scholar
• Yassa M, Fortin B, Fortin MA et al. Combined hypofractionated radiation and hormone therapy for the treatment of intermediate-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.71(1), 58–63 (2008).
   Google Scholar
• Faria SL, Souhami L, Joshua B et al. Reporting late rectal toxicity in prostate cancer patients treated with curative radiation treatment. Int. J. Radiat. Oncol. Biol. Phys.72(3), 777–781 (2008).
   Google Scholar
• Wu JS, Brasher PM, El-Gayed A et al. Phase II study of hypofractionated image-guided radiotherapy for localized prostate cancer: outcomes of 55Gy in 16 fractions at 3.4Gy per fraction. Radiother. Oncol.3(3), 127–132 (2012).
   Google Scholar
• Valeriani M, Monaco F, Osti MF et al. Hypofractionated radiotherapy with or without IGRT in prostate cancer: preliminary report of acute toxicity. Anticancer Res.31(10), 3555–3558 (2011).
   Google Scholar
• McCammon R, Rusthoven KE, Kavanagh B et al. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.75(2), 413–420 (2009).
   PubMed Web of Science ®Google Scholar
• Pervez N, Small C, MacKenzie M et al. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.76(1), 57–64 (2010).
   PubMed Web of Science ®Google Scholar
• Quon H, Cheung PC, Loblaw DA et al. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity. Int. J. Radiat. Oncol. Biol. Phys.82(2), 898–905 (2012).
   PubMed Web of Science ®Google Scholar
• Adkison JB, McHaffie DR, Bentzen SM et al. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.82(1), 184–190 (2012).
   PubMed Web of Science ®Google Scholar
• Livsey JE, Cowan RA, Wylie JP et al. Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. Int. J. Radiat. Oncol. Biol. Phys.57(5), 1254–1259 (2003).
   Google Scholar
• Kupelian PA, Willoughby TR, Reddy CA et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int. J. Radiat. Oncol. Biol. Phys.68(5), 1424–1430 (2007).
   PubMed Web of Science ®Google Scholar
• Martin JM, Rosewall T, Bayley A et al. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int. J. Radiat. Oncol. Biol. Phys.69(4), 1084–1089 (2007).
   PubMed Web of Science ®Google Scholar
• Leborgne F, Fowler J. Late outcomes following hypofractionated conformal radiotherapy vs. standard fractionation for localized prostate cancer: a nonrandomized contemporary comparison. Int. J. Radiat. Oncol. Biol. Phys.74(5), 1441–1446 (2009).
   PubMed Web of Science ®Google Scholar
• Lukka H, Hayter C, Julian JA et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J. Clin. Oncol.23(25), 6132–6138 (2005).
   PubMed Web of Science ®Google Scholar
• Yeoh EE, Botten RJ, Butters J et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of Phase III randomized trial. Int. J. Radiat. Oncol. Biol. Phys.81(5), 1271–1278 (2011).
   PubMed Web of Science ®Google Scholar
• Pollack A, Hanlon AL, Horwitz EM et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int. J. Radiat. Oncol. Biol. Phys.64(2), 518–526 (2006).
   PubMed Web of Science ®Google Scholar
• Norkus D, Miller A, Kurtinaitis J et al. A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma : a report on acute toxicity. Strahlenther. Onkol.185(11), 715–721 (2009).
   PubMed Web of Science ®Google Scholar
• Norkus D, Miller A, Plieskiene A et al. A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional conformal external-beam radiotherapy for localized prostate adenocarcinoma: a report on the first-year biochemical response. Medicina (Kaunas)45(6), 469–475 (2009).
   PubMed Web of Science ®Google Scholar
• Arcangeli G, Saracino B, Gomellini S et al. A prospective Phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.78(1), 11–18 (2010).
   PubMed Web of Science ®Google Scholar
• Dearnaley D, Syndikus I, Sumo G et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol.13(1), 43–54 (2012).
   PubMed Web of Science ®Google Scholar